MedTrace Logo

Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00010322 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2014-03-26

No results posted yet for this study

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Toremifene may fight breast cancer by blocking the uptake of estrogen by the tumor cells. Atamestane may fight breast cancer by blocking the production of estrogen. It is not yet known if toremifene is more effective with or without atamestane.

PURPOSE: Randomized phase III trial to compare the effectiveness of toremifene with or without atamestane in treating postmenopausal women who have metastatic breast cancer.

Conditions

Interventions

DRUG

atamestane

DRUG

toremifene

Sponsors & Collaborators

  • Intarcia Therapeutics

    lead INDUSTRY

Principal Investigators

  • Peter Langecker, MD, PhD · Intarcia Therapeutics

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2001-05-31
Completion
2001-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00010322 on ClinicalTrials.gov